 | Up a level |
Chowdhury, Simon, Shore, Neal D., Villers, Arnauld, Klotz, Laurence, Siemens, D. Robert, Baron, Benoit, van Os, Steve, Hasabou, Nahla, Wang, Fong, Forer, David and Heidenreich, Axel (2016). Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Heidenreich, Axel, Chowdhury, Simon, Klotz, Laurence, Siemens, David Robert, Villers, Arnauld, Ivanescu, Cristina, Holmstrom, Stefan, Baron, Benoit, Wang, Fong, Lin, Ping and Shore, Neal D. (2017). Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Eur. Urol., 71 (4). S. 534 - 543. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1873-7560
Siemens, D. Robert, Klotz, Laurence, Heidenreich, Axel, Chowdhury, Simon, Villers, Arnauld, Baron, Benoit, Van Os, Steve, Hasabou, Nahla, Brown, Scott, Wang, Fong, Forer, David and Shore, Neal D. (2016). EFFICACY AND SAFETY OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN YOUNGER AND OLDER PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN THE TERRAIN TRIAL. Asia-Pac. J. Clin. Oncol., 12. S. 117 - 118. HOBOKEN: WILEY-BLACKWELL. ISSN 1743-7563
Siemens, D. Robert, Klotz, Laurence, Heidenreich, Axel, Chowdhury, Simon, Villers, Arnauld, Baron, Benoit, van Os, Steve, Hasabou, Nahla, Wang, Fong, Lin, Ping and Shore, Neal D. (2018). Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. J. Urol., 199 (1). S. 147 - 155. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1527-3792
Tombal, Bertrand, Borre, Michael, Rathenborg, Per, Werbrouck, Patrick, Van Poppel, Hendrik, Heidenreich, Axel, Iversen, Peter, Braeckman, Johan, Heracek, Jiri, Baron, Benoit, Krivoshik, Andrew, Section, Mohammad Hirmand and Smith, Matthew R. (2018). Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naive Prostate Cancer: 3-Year Open Label Followup Results. J. Urol., 199 (2). S. 459 - 465. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1527-3792